Meglutin

Therapeutic Group

Indication Dosage

Meglumine Antimoniate is a medication primarily used for the treatment of visceral leishmaniasis, a parasitic infection caused by protozoa of the Leishmania genus. It is administered in an injectable form and works by targeting the parasites responsible for the disease, helping to alleviate symptoms and promote recovery in affected individuals.

Treatment Of Visceral Leishmaniasis (kala-azar): 

By IM Inj: 

• Adults: 20 Mg/kg Per Day (i.e. 75 Mg/kg Per Day Of Meglumine Antimony) Without Exceeding 850 Mg, For 20 Consecutive Days. Treatment Must Be Continued Until The Disappearance Of Parasites From Splenic Needle Aspirates Obtained At 14 Days Intervals. 

Treatment Of Cutaneous Leishmaniasis: 

Adults: 

• Local Treatment: Injection Of 1 To 3 Ml At The Base Of The Lesion, Repeated Once (or Twice If No Apparent Result Is Obtained) At 1 Or 2 Day Intervals. With The Exception Of Forms Due To L Braziliensis And L. Amazonensis: Lesions Should Be Envisaged Only At The Early Stage. 

By IM Inj: 

• Systemic Treatment: 10 To 20 Mg/kg Per Day, (i.e., 37 To 75 Mg/kg Per Day Of Meglumine Antimony) Until Clinical Cure Or Disappearance Of Parasites From Dermal Liquid Collected By Scarification, Then For A Few Extra Days.

Cutaneous Leishmaniasis Of L. Braziliensis And L Amazonensis: 

By IM Inj: 

• Adults: 20 Mg/kg Per Day (i.e., 75 Mg/kg Per Day Of Meglumine Antimony) Until Cure And For At Least 4 Weeks For L Braziliensis And For Several Months For L. Amazonensis.

Content

Pregnancy

Use Only If Potential Benefit Outweighs Risk.

Stability

Contra Indications

Precautions

Lactation

Side Effects